R1 RCM has received a noncompliance notice from Nasdaq’s Listing Qualifications Department resulting from R1’s delay in filing its quarterly report on Form 10-Q for the third quarter of 2023. Nasdaq’s ...

R1 RCM has launched a new tool designed to automate and streamline the prior authorization process at scale. The tool, called R1 Prior Authorization, manages the full authorization lifecycle through a ...

R1 RCM (NASDAQ:RCM) was downgraded to hold from buy at Deutsche Bank after the shares surged 25% on Monday after New Mountain offered to buy the company for $13.75 a share. Deutsche Bank downgraded ...

(Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would acquire the healthcare technology company in a deal that values it at $8.9 ...

Within the last quarter, R1 RCM (NASDAQ:RCM) has observed the following analyst ratings: In the last 3 months, 5 analysts have offered 12-month price targets for R1 RCM. The company has an average ...

In a report released today, Daniel Grosslight from Citi downgraded R1 RCM (RCM – Research Report) to a Hold, with a price target of $14.30. Daniel Grosslight has given his Hold rating due to a ...

Powered Technology with R1 Experts to Set a New Standard for Clearance and Denial RatesCHICAGO, Jan. 15, 2026 (GLOBE NEWSWIRE ...

MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare ...

MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

Cantor Fitzgerald Research analyst Sarah James initiated coverage on R1 RCM Inc. RCM with an Overweight rating and a price target of $20. The analyst is particularly upbeat about R1's client base, ...